Naoki Yoshioka

Naoki Yoshioka

Auto-generated profile, based on publicly available information

Naoki Yoshioka

Department of Cardiology, Ogaki Municipal Hospital, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2022 in Heart and Vessels
Verified
Journal Article
Closed access
PDF file
NYNaoki Yoshioka
Naoki Yoshioka
TTTakahiro Tokuda
Takahiro Tokuda
AKAkio Koyama
Akio Koyama
TYTakehiro Yamada
Takehiro Yamada
KSKiyotaka Shimamura
Kiyotaka Shimamura
TIthe ASIGARU PAD investigators
the ASIGARU PAD investigators

18 February 2024 in Journal of Endovascular Therapy
Verified
Journal Article
Closed access
KHKazunori Horie
Kazunori Horie
MTMitsuyoshi Takahara
Mitsuyoshi Takahara
TNTatsuya Nakama
Tatsuya Nakama
KTKazuki Tobita
Kazuki Tobita
ATAkiko Tanaka
Akiko Tanaka
MFMasahiko Fujihara
Masahiko Fujihara
Purpose: Surgical thromboendarterectomy has been the gold standard treatment for common femoral artery (CFA) disease. However, endovascular therapy (EVT) is conducted in certain patients with CFA lesions because of multiple comorbidities. The interwoven nitinol stent (IWS) has been developed to prevent stent fracture. Thus, this study aimed to evaluate the feasibility of EVT using IWS for CFA lesions in clinical practice. Materials and methods: This retrospective multicenter registry analyzed patients who had symptomatic lower-extremity artery disease due to CFA lesions and underwent EVT using IWS between 2019 and 2021. The primary endpoint was restenosis 2 years after EVT. Results: This study enrolled a total of 177 patients with 196 CFA lesions. The 2-year estimate of freedom from restenosis was 88.0%. The 2-year freedom rates from the target-lesion revascularization, major amputation, and all-cause death were 92.9%, 99.0%, and 75.2%, respectively. The clinical features significantly associated with restenosis risk were the reference vessel diameter (RVD, per 1.0 mm, hazard ratio [HR], 0.24 [0.08–0.70]; p=0.009), external iliac artery (EIA) involvement (HR=4.03 [1.56–10.4]; p=0.004), superficial femoral artery (SFA) involvement (HR=3.05 [1.00–9.25]; p=0.049), body mass index (BMI; per 1.0, HR=0.85 [0.73–0.99]; p=0.032), occlusion of deep femoral arteries (DFAs) at baseline (HR=7.89 [2.04–30.5]; p=0.003), and chronic limb-threatening ischemia (CLTI, HR=2.63 [1.02–6.78]; p=0.045). Their significant association was also confirmed by the random survival forest analysis. During a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases (37.2%), and no patients had cannulation-related complications, such as failed hemostasis, fracture of IWS, and stent occlusion. Conclusions: Endovascular therapy using IWS in CFA lesions showed acceptable 2-year patency rates at 88.0% and might preserve the arterial access via the ipsilateral CFAs. Small RVD, involving EIA and SFA lesions, emaciation, occluded DFA, and CLTI are associated with poor 2-year patency rates following EVT, thus, IWS implantation in CFA lesions may be an option for patients unsuitable for surgical revascularization. Clinical Impact: This retrospective multicenter registry enrolled 177 patients with 199 CFA lesions treated with EVT using interwoven nitinol stents, because surgical thromboendarterectomy was difficult due to their multiple comorbidities. The 2-year estimate of freedom from restenosis was acceptable at 88.0%. The 2-year freedom rate from major amputation was also high at 99.0%. Moreover, during a median follow-up of 12.0 months, guiding sheaths were inserted via CFAs implanted IWSs in 73 cases, and no patients had cannulation-related complications such as failed hemostasis, fracture of IWS, and stent occlusion.

1 November 2023 in Journal of Atherosclerosis and Thrombosis
Verified
Journal Article
Open access
PDF file
NYNaoki Yoshioka
Naoki Yoshioka
TTTakahiro Tokuda
Takahiro Tokuda
AKAkio Koyama
Akio Koyama
TYTakehiro Yamada
Takehiro Yamada
KSKiyotaka Shimamura
Kiyotaka Shimamura
OIon behalf of the ASIGARU PAD investigators
on behalf of the ASIGARU PAD investigators
Aim: Patients with chronic limb-threatening ischemia (CLTI) have a high bleeding risk (HBR) and mortality rate. The 2-year life expectancy is an important factor in deciding the appropriate treatment strategy. This study aimed to assess the influence of HBR on the prognosis of patients with CLTI. Methods: A total of 259 patients with CLTI who underwent endovascular therapy (EVT) (mean age, 76.2 years; male, 62.9%) between January 2018 and December 2019 were evaluated. The Academic Research Consortium for HBR (ARC-HBR) criteria were applied to each patient, and the ARC-HBR scores were calculated. The cut-off score for predicting all-cause mortality within two years was derived using a survival classification and regression tree (CART) model. Causes of death and the association between ARC-HBR scores and major bleeding events within two years were also investigated. Results: Based on the CART model, patients were divided into three groups (low HBR score 0–1.0, 48 patients; moderate HBR score 1.5–3.0, 176 patients; and high HBR score ≥ 3.5, 35 patients). During the study period, 82 patients (39.6%) died due to cardiac (n=23) and non-cardiac causes (n=59). All-cause mortality increased significantly with increasing ARC-HBR scores. Cox multivariate analysis revealed a significant association between high ARC-HBR scores and the risk of all-cause mortality within two years. Major bleeding events increased significantly with increasing ARC-HBR scores. Conclusions: The ARC-HBR score could predict 2-year mortality in patients with CLTI who underwent EVT. Thus, this score can help determine the best revascularization strategy for patients with CLTI.

25 April 2025 in Circulation Journal
Verified
Journal Article
Open access
PDF file
NYNaoki Yoshioka
Naoki Yoshioka
TTTakahiro Tokuda
Takahiro Tokuda
ATAkiko Tanaka
Akiko Tanaka
SKShunsuke Kojima
Shunsuke Kojima
KYKohei Yamaguchi
Kohei Yamaguchi
OIon behalf of the LEADers PAD Investigators
on behalf of the LEADers PAD Investigators
Background: Fluoropolymer-coated drug-eluting stents (FP-DESs) are widely used to treat femoropopliteal artery (FPA) disease. However, data on the pattern and timing of recurrence after FP-DES implantation are limited. This study aimed to address this knowledge gap.Methods and Results: This multicenter retrospective study analyzed 439 limbs of 398 patients treated with FP-DESs for de novo FPA lesions. The outcome measures were clinical outcomes in cases of recurrence, defined as a composite of restenosis and reocclusion. The timing of recurrence was categorized into early (within 1 year of treatment) and late (after 1 year). The factors associated with recurrence were analyzed by comparing cases of early and late recurrence. The early recurrence group showed a significantly higher frequency of reocclusion, particularly stent thrombosis. In addition, in this group, patients with reocclusion tended to exhibit significantly more severe clinical symptoms than those with restenosis. Deployment of FP-DES beyond the P1 segment was independently associated with early recurrence. Chronic total occlusion was independently associated with early reocclusion. Female sex, diabetes, not using statins, and long lesions were independently associated with late recurrence. Not using statins, warfarin use, and long lesions were independent predictive factors for late reocclusion.Conclusions: The patterns and clinical symptoms of recurrence after FP-DES implantation for FPA differed according to the timing of recurrence, as did the factors associated with recurrence.

24 March 2025 in Vascular Medicine
Verified
Journal Article
Closed access
NYNaoki Yoshioka
Naoki Yoshioka
TTTakahiro Tokuda
Takahiro Tokuda
ATAkiko Tanaka
Akiko Tanaka
SKShunsuke Kojima
Shunsuke Kojima
KYKohei Yamaguchi
Kohei Yamaguchi
IMItsuro Morishima
Itsuro Morishima
Background: Paclitaxel-coated balloons (PCBs) are widely used for femoropopliteal artery (FPA) diseases. However, data on recurrence and recurrence patterns after PCB angioplasty are limited. This study investigated the association between recurrence patterns, baseline characteristics, and clinical outcomes in the cases following PCB angioplasty. Methods: This multicenter, retrospective study included 1159 limbs in 1031 patients treated for de novo FPA lesions using PCBs. Patients were classified into three groups (patency, restenosis, and reocclusion) according to patency or recurrence patterns within 2 years after the index PCB angioplasty. The primary outcome was the incidence of target lesion revascularization (TLR), and the secondary outcome was the pattern of re-recurrence within 2 years following TLR using PCBs. Results: When comparing the three groups, reocclusive cases were characterized by more complex lesions, including chronic total occlusion, at baseline. Following the index PCB angioplasty, approximately 70% of recurrent cases underwent TLR, which was performed more frequently in reocclusive than in restenotic cases (82.1% vs 63.7%). Conversely, a higher percentage of restenotic cases did not require TLR compared to reocclusive cases (10.3% vs 27.8%). In cases where TLR was performed using PCBs, the rate of re-recurrence with occlusive morphology was significantly higher in reocclusive than in restenotic cases (52.3% vs 24.3%). Conclusions: After PCB angioplasty for FPA lesions, symptomatic recurrence and requirement for TLR were more frequent in reocclusive cases. Even after TLR using PCBs, reocclusive cases tend to recur with occlusion.

24 December 2024 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
TYTakehiro Yamada
Takehiro Yamada
TTTakahiro Tokuda
Takahiro Tokuda
NYNaoki Yoshioka
Naoki Yoshioka
AKAkio Koyama
Akio Koyama
RNRyusuke Nishikawa
Ryusuke Nishikawa
TATakuma Aoyama
Takuma Aoyama